5-(p-Tolyl)-1,3,4-oxadiazol-2-amine

Catalog No.: 
ACQRVZ148
CAS No.: 
33621-60-2
Molecular Formula: 
C9H9N3O
Molecular Weight: 
175.19
5-(p-Tolyl)-1,3,4-oxadiazol-2-amine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$117.00In stockInquiry
1g97%$262.00InquiryInquiry
5g97%$765.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(p-Tolyl)-1,3,4-oxadiazol-2-amine
IUPAC Name5-(p-tolyl)-1,3,4-oxadiazol-2-amine
MDL No.0
Molecular FormulaC9H9N3O
Molecular Weight175.19
SMILESNC1=NN=C(C2=CC=C(C)C=C2)O1
InChI KeyAXAUHVYAAUVJQR-UHFFFAOYSA-N
Synonym5-(4-methylphenyl)-1,3,4-oxadiazol-2-amine;[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]amine;5-(4-methylphenyl)-1,3,4-oxadiazol-2-ylamine;5-(p-tolyl)-1,3,4-oxadiazol-2-amine;JR-13808, 5-p-Tolyl-1,3,4-oxadiazol-2-amine, 95%;1,3,4-Oxadiazol-2-amine, 5-(4-methylphenyl)-
CAS No.33621-60-2
PubChem CID356898

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACQRVZ148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQRVZ148 route product structure diagram
    ACQRVZ14833621-60-2In Stock
Inquiry

2. ACQRVZ148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQRVZ148 route product structure diagram
    ACQRVZ14833621-60-2In Stock
Inquiry

3. ACQRVZ148 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACQRVZ148 route product structure diagram
    ACQRVZ14833621-60-2In Stock
Inquiry

Comments (0)